Positive Results Presented from Proof-of-Concept Phase II Clinical Trial of Incyte’s Oral JAK1 Inhibitor in Patients with

  Positive Results Presented from Proof-of-Concept Phase II Clinical Trial of
  Incyte’s Oral JAK1 Inhibitor in Patients with Chronic Plaque Psoriasis

  *In data presented at EADV, treatment with INCB39110 achieved efficacy in
    multiple psoriasis severity measures as compared to placebo over four
    weeks of therapy
  *INCB39110 was generally well-tolerated, with no evidence of
    myelosuppression

Business Wire

ISTANBUL -- October 3, 2013

Incyte Corporation (Nasdaq: INCY) announced results from a 28-day,
placebo-controlled, dose-escalation Phase II proof-of-concept clinical trial
involving 50 patients with chronic plaque psoriasis for its proprietary oral
JAK1 inhibitor, INCB39110. The results were presented by Robert Bissonnette,
M.D., President of Innovaderm Research Inc. and co-lead investigator, today at
the European Academy of Dermatology and Venereology (EADV) Congress in
Istanbul, Turkey.

In the trial, evidence of efficacy was observed in patients treated with
INCB39110 at all doses as measured by static physician global assessment
(sPGA) and psoriasis area and severity index (PASI) as compared to patients
treated with placebo. INCB39110 was generally well-tolerated with no evidence
of myelosuppression.

Dr. Bissonnette stated, “These initial results with INCB39110 are encouraging
and demonstrate the agent’s anti-inflammatory activity and the therapeutic
potential of JAK1 inhibition in psoriasis.”

Summary of Study Results

The results of the Phase II clinical trial were reported during an oral
presentation, A Double-Blind, Placebo-Controlled Study Exploring the Safety,
Tolerability, and Efficacy of a 28-Day Course of Escalating Doses of an Oral
JAK1 Inhibitor in Subjects with Stable, Chronic Plaque Psoriasis. The trial
evaluated four doses of INCB39110, specifically 100 mg once daily, 200 mg once
daily, 200 mg twice daily and 600 mg once daily.

The primary endpoint of the study was the mean percent change from baseline in
sPGA score at Day 28, and the secondary endpoints were the percentage of
patients achieving sPGA 0 or 1 (clear or minimal) and the percentage of
patients achieving PASI 50.

The study demonstrated evidence of efficacy as assessed by sPGA at all doses
(ranging from -22.2% to -42.4% mean change in sPGA) as compared to placebo
(-12.5% mean change in sPGA). The data also showed efficacy in terms of the
percentage of patients who achieved clear or almost clear sPGA (ranging from
11.1% to 45.5% for all doses of INCB39110 vs. 0% for placebo) and PASI 50
(ranging from 22.2% to 81.8% for all doses of INCB39110 vs. 8.3% for placebo).

Exploratory efficacy analyses suggested that efficacy was approximately equal
in patients with greater than 10 percent body surface area involvement and in
patients with 5 to 10 percent body surface area involvement prior to
treatment.

The compound was generally well-tolerated with no evidence of
myelosuppression. Decreases in platelet counts were observed, but the counts
generally remained within normal limits. Increases in LDL and HDL were also
noted without a significant change in the HDL/LDL ratio.

To access the presentation: INCB39110 EADV Presentation

“Our proof-of-concept studies of INCB39110 in psoriasis, rheumatoid arthritis
and myelofibrosis are providing us with greater insight and confirm our belief
that JAK1 inhibition may be of benefit in chronic inflammatory disorders as
well as oncologic indications,” stated Richard S. Levy, Incyte’s Executive
Vice President and Chief Drug Development and Medical Officer. “With our
portfolio of JAK1 inhibitors, we’re well-positioned to potentially pursue
development in chronic inflammatory conditions and oncology with separate
molecules, as we did with our JAK1/JAK2 inhibitor program.”

About INCB39110

INCB39110 is the most advanced compound within Incyte’s portfolio of selective
JAK1 inhibitors and is being evaluated in Phase II proof-of-concept trials in
psoriasis, rheumatoid arthritis and myelofibrosis and an initial Phase I/II
safety study in combination with gemcitabine and nab-paclitaxel in patients
with advanced solid tumors to help define its clinical efficacy and safety
profile, understand potential points of differentiation between JAK1 and
JAK1/JAK2 inhibition and determine the most appropriate path forward for
further development.

About Incyte

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company
focused on the discovery, development and commercialization of proprietary
small molecule drugs for oncology and inflammation. For additional information
on Incyte, please visit the Company's website at www.incyte.com.

Forward-Looking Statements

Except for the historical information set forth herein, the matters set forth
in this press release, including without limitation statements with respect to
the potential efficacy and safety and therapeutic potential of INCB39110, our
belief that JAK1 inhibition may be of benefit in chronic inflammatory
disorders as well as oncologic indications, and our potential to pursue
development in chronic inflammatory conditions and oncology with separate JAK1
inhibitor molecules, contain predictions and estimates and are forward-looking
statements within the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. These forward-looking statements are
based on Incyte’s current expectations and subject to risks and uncertainties
that may cause actual results to differ materially, including unanticipated
developments in and risks related to the efficacy or safety of INCB39110, the
results of further research and development, other market, economic or
strategic factors and technological advances, and other risks detailed from
time to time in Incyte's filings with the Securities and Exchange Commission,
including its Quarterly Report on Form 10-Q for the quarter ended June 30,
2013. Incyte disclaims any intent or obligation to update these
forward-looking statements.

Contact:

Incyte Corporation
Pamela M. Murphy
Vice President, Investor Relations & Corporate Communications
302-498-6944
 
Press spacebar to pause and continue. Press esc to stop.